Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06926075
Registration number
NCT06926075
Ethics application status
Date submitted
20/03/2025
Date registered
13/04/2025
Date last updated
13/04/2025
Titles & IDs
Public title
Early Phase Study of Kesonotide in Participants With Solid Tumours
Query!
Scientific title
An Adaptive Phase I/II Study of Kesonotide, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours
Query!
Secondary ID [1]
0
0
FLM-CT002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ADVICE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostate Cancers
0
0
Query!
Breast Cancer
0
0
Query!
Lung Cancers
0
0
Query!
Ovarian Cancer
0
0
Query!
Glioblastoma Multiforme (GBM)
0
0
Query!
Pancreas Cancer
0
0
Query!
Skin Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Brain
Query!
Cancer
0
0
0
0
Query!
Pancreatic
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - A novel hGIIA-Vimentin Inhibitor
Treatment: Drugs - Dose expansion
Experimental: Phase I, Single Arm, dose escalation -
Experimental: 2 Arms of selected indication and recommended dose -
Treatment: Drugs: A novel hGIIA-Vimentin Inhibitor
Phase I, dose escalation includes 4 increasing doses, 10mg, 30mg, 60mg and 120mg.
Treatment: Drugs: Dose expansion
Phase II will enrol participants in selected indication(s) and will be given one of the two recommended doses by the SMC.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
To evaluate the safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers.
Query!
Assessment method [1]
0
0
Incidence of serious adverse events (SAEs)
Query!
Timepoint [1]
0
0
Cycle 1 (21 days)
Query!
Primary outcome [2]
0
0
To evaluate the safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers.
Query!
Assessment method [2]
0
0
Treatment emergent adverse effects (TEAEs)
Query!
Timepoint [2]
0
0
Cycle 1 (21 days)
Query!
Primary outcome [3]
0
0
To evaluate the safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers.
Query!
Assessment method [3]
0
0
Incidence and nature of dose-limiting toxicities (DLTs).
Query!
Timepoint [3]
0
0
Cycle 1 (21 days)
Query!
Primary outcome [4]
0
0
To evaluate the safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers.
Query!
Assessment method [4]
0
0
Changes in vital sign measurements (Hear rate in beats per minute, blood pressure in systolic and diastolic mm Hg)
Query!
Timepoint [4]
0
0
Cycle 1 (21 days)
Query!
Primary outcome [5]
0
0
To evaluate the safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers.
Query!
Assessment method [5]
0
0
Clinical safety laboratory parameters (abnormal haematology, clinical chemistry and coagulation blood tests; pregnancy test, as per CTCAE v5.0 classification
Query!
Timepoint [5]
0
0
Cycle 1 (21 days)
Query!
Primary outcome [6]
0
0
To evaluate the safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers.
Query!
Assessment method [6]
0
0
Electrocardiogram (ECG) parameters (Heart Rate, PR Interval, P wave, QRS Complex, T wave, ST Segment, QT Interval)
Query!
Timepoint [6]
0
0
Cycle 1 (21 days)
Query!
Primary outcome [7]
0
0
To evaluate the safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers.
Query!
Assessment method [7]
0
0
Eastern Cooperative Oncology Group (ECOG) performance status findings.
Query!
Timepoint [7]
0
0
Cycle 1 (21 days)
Query!
Eligibility
Key inclusion criteria
* Male or female adults (defined as = 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).
* Has an ECOG performance status score of 0 or 1.
* Has a life expectancy of > 12 weeks in the opinion of the investigator.
* Measurable or evaluable disease by CT/MRI according to RECIST v1.1, except for prostate and breast cancer (bone only metastases are acceptable) and glioma.
* Histologically or cytologically confirmed locally advanced/metastatic solid cancers.
* Has adequate organ function within 7 days prior to Day 1 of Cycle 1, defined as below:
* Laboratory Value
* Hematology
* Platelet count > 100 x 109/L
* Hb > 9.0 g/dL
* ANC > 1.5 x 109/L
* Renal Function
* Creatinine < 1.5 x ULN
* Hepatic Function
* AST and ALT < 3 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases
* Total bilirubin = 1.5 x ULN
* Serum albumin = 2.5 g/dL
* INR/PT and APTT = 1.5 x ULN
* Male and female participants of reproductive/childbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) for at least 90 days during the study and after the last dose of study drug.
* Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 90 days after the final study drug administration.
* Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and at least 90 days after the final study drug administration.
* Has failed standard of care or refused next line therapy at the present time and if approved treatment options are still available, can delay approved treatments without harm as judged by the investigator (e.g., patients requesting a break between lines of therapy).
Additional Inclusion Criteria for Parts 2 and 3:
* Measurable disease (as defined for Part 1) or recognised and abnormal biomarker levels (e.g., PSA for prostate cancer, CA15.3 for breast cancer).
* Defined diseases or disease states of interest, suitable for dose expansion.
* Patients who have enrolled in Part 1 of the study (dose-escalation), and in the opinion of the investigator, are benefitting from treatment, may be eligible for Parts 2 and 3.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Participants who are unable to cease any anti-inflammatory medications or statins prior to and during the study, including non-steroidal anti-inflammatories, oral steroids at any dose; topical steroids and anti-inflammatories are allowable.
* Participants who have participated in other clinical trials and received investigational products within 4 weeks, or within five half-lives of the treatment, whichever is longer, before Cycle 1 Day 1 of the study period.
* Previous adverse reactions which have not returned to Grade 0 or 1 according to NCI-CTCAE v5.0 (except alopecia and fatigue) at the screening visit.
* A clinically significant active infection determined by the investigator.
* Significant or recurrent third space accumulation (e.g., ascites or pleural effusions) according to the investigator.
* Has a medical history of myocardial infraction or unstable angina within 6 months before enrolment.
* Has a medical history of symptomatic CHF (New York Heart Association (NYHA) classes II-IV) or serious cardiac arrhythmia requiring treatment.
* Has a history or presence of uncontrolled mental illness.
* The participant is expected to be non-compliant with critical trial procedures and is not willing or able to adhere to the trial requirements during the study.
* Participants are deemed inappropriate for this clinical trial at the discretion of the investigator.
Additional Exclusion Criteria for Parts 2 and 3:
- Patients must not have more than 2 prior lines of therapy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
26/05/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
26/10/2027
Query!
Actual
Query!
Sample size
Target
80
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Filamon LTD
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of kesonotide. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06926075
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Admir Huseincehajic
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61467451064
Query!
Fax
0
0
Query!
Email
0
0
admir.huseincehajic@filamon.com
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06926075
Download to PDF